High prevalence and risk factors of transmission of hepatitis delta virus in

pregnant women in the Center Region of Cameroon

- 4 Juliette-Laure Ndzie Ondigui ^{1,2}, Email : <u>njulielaure@gmail.com</u>
- 5 Nadège Mafopa Goumkwa ², Email : <u>g.m.nadege@gmail.com</u>
- 6 Cindy Lobe^{2,3}, Email: <u>lobecindy@hotmail.com</u>
- 7 Brigitte Wandji⁴, Email: wandji.brigitte@yahoo.com
- 8 Patrick Awoumou^{5,2}, Email: patrick26lebon@gmail.com
- 9 Prisca Voussou Djivida⁵, Email : <u>djividaprisca@yahoo.fr</u>
- Puinta Peyonga⁵, Email : <u>puipen@yahoo.com</u>
- 11 Solange Manju Atah⁶ Email : <u>solangeneh36@gmail.com</u>
- 12 Vivian Verbe⁷, Email : visale@yahoo.com
- Rachel Kamgaing Simo², Email: <u>r.kamgaing@yahoo.it</u>
- 14 Sylvie Agnès Moudourou², Email : sylvie.moudourou@gmail.com
- 15 Ana Gutierrez⁹, Email: anagutiaci@yahoo.es
- 16 Rosi Garcia⁹, Email: rosi.acibikop@gmail.com
- 17 Isabelle Fernandez⁹, Email : i.fernandez@esclavasaci.es
- Sara Honorine Riwom Essama¹, Email: sarariwom@yahoo.fr
- 19 Robinson Mbu^{4,10}, Email : robinsonmbu@gmail.com
- 20 Judith Torimiro^{2,5*}, Email: jn.torimiro@gmail.com
- 22 1-Department of Microbiology, Faculty of Sciences, University of Yaoundé 1, Yaounde,
- 23 Cameroon;

21

1

2

- 24 2- "Chantal BIYA" International Reference Center for research on HIV/AIDS prevention and
- 25 management (CIRCB), Yaounde, Cameroon;
- 3- Department of Food Science and Nutrition, National School of Agro-Industrial Sciences,
- 27 University of Ngaoundere, Ngaoundere, Cameroon;
- 28 4- Yaoundé Gyanecology Obstetrics and Paediatrics Hospital, Yaounde, Cameroon;
- 29 5- Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of
- 30 Yaounde 1, Yaounde, Cameroon;
- 31 6-Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
- 32 Yaounde 1, Yaounde, Cameroon;

7-Cité Verte District Hospital, Yaounde, Cameroon; 8- Biyem-Assi District Hospital, Yaounde, Cameroon 9- Bikop Catholic Health Center, Bikop, Cameroon 10- Department of Gynecology/Obstetrics, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon **Authors Contributions** Designed the study: Judith Torimiro, Robinson Mbu, Sara Honorine Riwom Essama, Juliette-Laure Ndzie Ondigui; Collected the data: Judith Torimiro, Juliette-Laure Ndzie Ondigui, Brigitte Wandji, Patrick Awoumou, Puinta Peyong, Prisca Voussou Djivida, Vivian Verbe, Eveline Tincho Foguem, Rachel Kamgaing Simo, Sylvie Agnès Moudourou, Ana Gutierrez, Rosi Garcia, Isabelle Fernandez: Analyzed and interpreted the data: Juliette-Laure Ndzie Ondigui, Nadège Mafopa Goumkwa, Cindy Lobe, Judith Torimiro; Initiated and drafted the manuscript: Juliette-Laure Ndzie Ondigui, Nadège Mafopa Goumkwa, Judith Torimiro; Revised the manuscript: all the authors read and approved the final manuscript. *Corresponding author: Judith Torimiro Email: jn.torimiro@gmail.com

ABSTRACT

64

68

69

73

74

75

77

81

82

85

86

88

90

92

93

Background: Hepatitis B virus (HBV) and hepatitis delta virus (HDV) co-infection has been described as the most severe form of viral hepatitis, and both can be co-transmitted from mother-to-child. A seroprevalence of 4.0% of HDV infection was reported in pregnant women

in Yaoundé, and 11.9% in the general population in Cameroon. Our objective was to describe

the rate of HDV infection in pregnant women and to determine risk factors associated with

70 mother-to-child transmission of HDV.

71 Materials and Methods: A cross-sectional, descriptive study was conducted from January

72 2019 to July 2022 among pregnant women attending antenatal contacts in seven health

structures in the Centre Region of Cameroon. A consecutive sampling (non-probability

sampling) was used to select only women of age over 21 years, who gave a written informed

consent. Following an informed consent, an open-ended questionnaire was used for a

Knowledge, Attitude and Practice (KAP) survey of these women, and their blood specimens

collected and were screened for HBsAg, anti-HIV and anti-HCV antibodies by rapid tests and

78 ELISA. HBsAg-positive samples were further screened for HBeAg, anti-HDV, anti-HBs, and

anti HBc antibodies by ELISA, and plasma HDV RNA load measured by RT-qPCR.

Results: Of 1992 pregnant women, a rate of 6.7% of HBsAg (134/1992) with highest rate in

the rural areas, and 3.9% of hepatitis vaccination rate were recorded. Of 134, 44 (32.3%) were

anti-HDV antibody-positive, and 47.6% had detectable RNA viraemia. Two women of 44 anti-

HDV-positive cases (4.5%) were co-infected with HBV and HCV, while 5 (11.4%) with HIV

and HBV. Multiple deliveries, the presence of tattoos and/or scarifications were significantly

statistically associated with the presence of anti-HDV antibodies. Of note, 80% of women with

negative HBeAg and positive anti-HBe serological profile, had plasma HDV RNA load of more

87 than $\log 3.25$ (>10.000 copies/ml).

Conclusion

These results show an intermediate rate of HDV infection among pregnant women with high

level of HDV RNA viremia, which suggest an increased risk of vertical and horizontal co-

91 transmission of HDV.

Keywords: risk factors, transmission, hepatitis delta virus, pregnancy

Introduction

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

Hepatitis B virus (HBV) is the aetiologic agent of hepatitis B. The WHO estimates that 296 million people were living with chronic hepatitis B in 2019 with 1.5 million new infections each year[1], whereas Hepatitis delta virus (HDV) affects nearly 5% of people with chronic hepatitis B worldwide[1]. HDV requires the presence of HBV in order to replicate [2-4] in coinfection or super-infection causing the most serious form of chronic viral hepatitis, given its more rapid progression to hepatocellular carcinoma and death [5-8]. It is also worth noting, the low HBV vaccination rate among pregnant women in Cameroon of less than 2.5% [9]. HBV and HDV can be transmitted through skin lesions (injection, scarification, tattooing), contact with infected blood or blood products, but mostly they are co-transmitted through sexual intercourse and from mother-to-child [10]. Therefore, pregnant women are an index population for both vertical and horizontal transmission of HBV and HDV. However, certain practices favour the transmission of HBV in the Centre Region of Cameroon. They include poor accessibility to healthcare, low rate of vaccination, cultural and traditional beliefs, low rate of condom use, high rate of early age of first sexual intercourse, low rate of official marriage, high rate of home delivery, poor link to prevention of mother-to-child transmission (PMTCT) activities, and to other maternal-infant disease prevention efforts in Cameroon. HBV/HDV co-transmission from mother-to-child has been described [11, 12]. It is an event that seems rare but remains possible and the risk could increase with high level of plasma load of HBV DNA and HDV RNA in the pregnant woman [13-15], in individuals with multiple sexual partners and/or with scarification [16]. Vaccination against hepatitis B is an effective strategy to prevent HDV infection. Therefore, scaling-up the national vaccination programme against hepatitis B in the general population, could lead to a drop in the incidence of hepatitis D worldwide. In 2018, it was reported that 83.3% of pregnant women attending ANC in Yaounde, Cameroon, knew that vaccination against HBV infection is a method of prevention, and 47.1% knew that HBV could be transmitted from mother-to-child. However, only 2.5% had received three doses of the hepatitis B vaccine [9, 17]. In Cameroon the seroprevalence of HBV (HBsAg) in the general population is 11.2%, about two to three times higher than that of the human immunodeficiency virus (HIV) of 3.4% [18, 19]. In 2021, the Cameroon Ministry of Public Health reported a seroprevalence among pregnant women at first trimester of 5.0% in the Centre Region where this study was carried out against 8.63% of national prevalence [20]. In addition, in Central Africa, HDV seroprevalence is estimated at 25.64% in the general population [7], compared to 46.73% in Cameroon in 2018 [21].

- Low hepatitis B vaccination coverage in the sexually active population, and lack of recent
- epidemiological data on HDV in pregnant women, show that the general population in
- 129 Cameroon is at risk of continuous spread of HBV and HDV from mother-to-child and
- horizontally. Thus, our specific objectives were to determine the rates of HDV infection and
- factors associated with risk of HDV infection among pregnant women.

Materials and methods

Study design, enrollment procedure and eligibility criteria

- A cross-sectional study was conducted from January 2019 to July 2022 in a tertiary hospital,
- five District hospitals, and one rural Health Center in the Center Region of Cameroon, among
- pregnant women attending ANC. A total of 1992 pregnant women of age over 21 years were
- enrolled (Figure 1) from an anticipated 1475 participants deduced from a statistical formula
- shown below [22] which is commonly used to determine the minimum sample size in medical
- 139 studies:

132

- 140 $n = (Z\alpha)2 p (1-p)/d2$
- 141 where:
- $Z\alpha$ = standard normal variate (1.96 for a 95% confidence interval);
- p= prevalence of HDV among pregnant women in Cameroon (4.0) [9];
- 144 d = precision of the estimate (0.01).
- Substituting the figures in the above formula yields 1475.2 (nearest whole number). Thus, a
- minimum of 1475 participants was required.
- Data collection took place in 3 stages. Before enrolling the participants, a group sensitization
- at the hospital or Health Center was conducted to raise awareness on hepatitis B transmission
- and prevention, hepatitis B and pregnancy, the importance of HBV screening and the purpose
- of the study. Thereafter, 1992 subjects who were willing to be part of the study, were
- administered a Consent Form, and upon their consent, a questionnaire with open-ended
- questions was administered to collect personal and socio-demographic data, their knowledge,
- attitude and practices with respect to hepatitis B. Some women who took part in the sensitization
- campaign were not enrolled in the study because they had to have the opinion of their partners,
- or did not give any reason.

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

A consecutive sampling (non-probability sampling) was used to select only pregnant women of age over 21 years, who gave a written informed consent. In order to avoid any confusion and to preserve the anonymity of the participants, each participant was assigned a code that allowed us to link each questionnaire to its corresponding blood specimen, while another Register of the ANC used only by hospital staff was established to link the subjects to their results. This same code was used throughout the analysis in the laboratory and the results were linked to the identity of the subject by the hospital staff and not by the research team. Laboratory procedures After completing the questionnaire, 5 ml of blood was drawn from 1992 subjects into a tube containing ethylene-diamine-tetra-acetic acid (EDTA), processed and the plasma tested for HBsAg, anti-HIV and anti-HCV antibodies using rapid diagnostic tests (RDT. ABON. Determine HIV1/2 and KHB Diagnostic kit for HIV antibodies 1 + 2) and ELISA (Murex HBsAg, and Murex HCV Ab), following the manufacturer's instructions. Furthermore, the HBsAg-positive samples were tested by ELISA for other HBV infection biomarkers: anti-HBs, anti-HBc, HBeAg, and anti-HBe. Positive and negative plasma controls were run alongside each test, following the National Testing Algorithms for these viruses in Cameroon. ELISA was performed to detect anti-HDV antibodies in 134 plasma samples using the ETI-DELTA-IGMK-2 kit (Dia. Pro Diagnostic Bioprobes srl, Italy). Quantification of HDV RNA (viral RNA load) by real-time qRT-PCR (Eurobioplex HDV Kit, Eurobio Scientific, France) was performed using 34 anti-HDV positive plasma samples. All serologic results were made available to the women within two weeks after specimen collection. The rapid test results were confirmed by two technicians and the samples with borderline results, were further analyzed by ELISA. On the other hand, plasma HDV RNA load was quantified by qRT-PCR commercial kit that detects all 8 main genotypes of HDV, with a lower limit of detection of 100IU/mL. Through these analyses, the subjects that were infected with HBV and/or HDV, were identified. These results were linked to the reported answers given by each subject in relation to their knowledge on modes of transmission and prevention of HBV, their attitude towards prevention of HBV infection such as vaccination and unprotected sex, as well as their practices that predisposes them to acquiring HBV and/or HDV. All women who tested positive for HBsAg were offered post-test counselling on their status, modes of hepatitis B transmission, need for testing of close contacts for hepatitis B, and vaccination of baby within the first twenty four hours of life against hepatitis B. They were then

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

referred for clinical evaluation and management to a gastroenterologist, and those who were negative for HBsAg were advised to get vaccinated if not yet. Statistical analysis Data collected was regularly checked, corrected, recorded and processed using IBM.SPSS. Statistics.v20 software, while ensuring anonymity with the use of subject registration code. Frequencies of qualitative data were estimated as means. Using internal negative and positive controls in each run, a cycle threshold (Ct) of \leq 35 was considered positive, and Ct > 35 and \leq 45 was considered a non-quantifiable positive result. Using a standard curve drawn from standards provided by the manufacturer, the HDV RNA load was extrapolated to copies/mL which was then multiplied by a factor (0.18) to convert into IU/mL. The analysis of the relationship between the prevalence and the different characteristics of the sample was done by logistic regression. Using the Pearson Chi-2 test, the factors associated with HBV and HDV infection, were determined with p values <0.05 considered statistically significant. Ten samples with missing data were not included in the analysis. **Ethical considerations** The study was conducted in accordance with the fundamental principles of the Declaration of Helsinki, with administrative and ethical approval from health facilities and laboratories, as well as the National Ethics Committee for Human Health Research in Cameroon (N° 2018/06/1150/L/CNERSH/SP), respectively. A written informed consent was obtained from all participants, data was recorded using unique identifiers to ensure confidentiality, and laboratory results were returned to participants for potential benefits in their clinical management. The subjects positive for HBsAg antigen were referred to a gastroenterologist and those HBsAgnegative were advised to be vaccinated if not yet. Results Socio-demographic parameters and Knowledge, Attitude and Practices of pregnant women Overall, 1992 pregnant women were tested for HBsAg, with a mean age of 27.53 ± 5.68 years. The average gestational age was 17 ± 6 weeks, with a majority of the women at the second trimester pregnancy. One thousand nine hundred and thirteen (1913) women have never received the hepatitis B vaccine, but 56 had received three doses of the vaccine (2.8%) (Table 1). One thousand six hundred and twenty seven (1627) women were screened for the first time

- 219 for HBsAg during this study (81.7%). In the group of HBsAg-positive women, 53(39.9%)
- women were in their first pregnancy, 75 (56.4%) lived with a partner, 37 (27.8%) knew their
- partner's hepatitis B status and 5.4% (2/37) of their partners were positive for HBsAg, 15
- 222 (11.3%) had already been tattooed or scarified and 21 (15.7%) had a history of surgery.

Prevalence of HDV and HBV Infection markers

223

236237

247

248

- Of 1992 pregnant women tested for HBsAg, 133 were positive (6.7%) while 9.8% of women
- in the third trimester were HBsAg-positive, and 9.9% of them live in the rural area. Of these,
- 42 samples were positive for anti-HDV antibodies by serology, with 62.5% with detectable
- plasma HDV RNA. Meanwhile, rates of 9.0%, 79.7% and 94.0% for HBeAg, anti-HBe and
- anti-HBc, respectively, was recorded for the HBsAg-positive specimens. Table 2 shows the
- distribution of serological markers of hepatitis B infection (HBeAg, HBeAb and HBcAb) as a
- 230 function of the presence of anti-HDV antibodies, indicating that HBeAg was statistically
- significantly associated with the presence of anti-HDV antibodies (p = 0.008). Two (4.8%)
- women were co-infected with HCV, HBV and HDV, and 5 (11.9%) with HIV, HBV and HDV.
- 233 However, HBV/HIV and HBV/HCV co-infections were not associated with anti-HDV
- positivity in this study. In univariate analysis, neither of HIV nor HCV serologic positivity was
- associated statistically significantly with the presence of anti-HDV antibodies (Table 2).

Factors associated with hepatitis delta virus infection

- Our study shows that 4 women with more than 5 children were positive for anti-HDV
- antibodies. In addition, women living with a partner (44.0%) were more exposed than women
- living alone (16.4%) to be infected with HDV (p=0.001), while 60.0% of women who had been
- 241 tattooed or scarified had anti-HDV antibodies (p=0.015) (Table 3). Comparing the
- 242 seroprevalence of HDV antibodies against biomarkers of HBV infection, there was a
- statistically significant difference with the presence of anti-HBc (p=0.008), anti-HBe (p=0.001)
- and HBeAg-negative/Anti-HBe+ (p=0.005). Of note, the HBeAg-negative/anti-HBe-positive
- 245 profile was the most frequently detected amongst those with plasma HDV RNA viral load of
- 246 more than log 3.25 (10.000 copies/mL) (Table 4).

Discussion

- We studied the seroprevalence of anti-HDV antibodies and the presence of plasma HDV RNA
- in 130 HBsAg-positive samples, detected in a sample of 1992 pregnant women collected
- between January 2019 and July 2022 in seven health structures in the Centre Region of

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

Cameroon. Overall, we observed a seroprevalence of HBsAg of 6.7%. These results are close to those obtained by Torimiro et al in 2018 (6.4%) among pregnant women in Yaoundé, Cameroon [9]. In comparison to other African countries with similar socio-economic and public health contexts, such as Nigeria, Gabon and Burkina Faso, similar prevalence has been reported [23, 24]. We also noted that in our study population the prevalence of HBsAg is higher among pregnant women in rural areas compared to those in urban areas. Other studies conducted in rural areas in Cameroon, have recorded higher prevalence ranging from 7.5% to 13.7% [25-27]. This moderate to high prevalence of hepatitis B in rural areas in Cameroon could be related to the low level of knowledge about hepatitis B modes of transmission and prevention, and risk factors of attitude and practices including idleness and promiscuity. In other words, these are factors that would favour transmission of HDV. Although the efficacy of the hepatitis B vaccine has been proven and has been available since 2005 in the Cameroon EPI [28], this study shows that vaccination coverage remains very low among women of child-bearing age, which contributes in keeping the pool of index infected sub population on the increase. It is therefore not unusual to detect the high prevalence of HDV infection in pregnant women in the Centre Region of Cameroon. Since 1991 when the first study on the prevalence of HDV was conducted in Cameroon[29], several studies have been carried out in the general population or among people with particular socio-demographic characteristics such as pygmies. The variations in the prevalence of anti-HDV antibody ranged from 10.5% to 69% [16, 21, 30-32]. On the other hand, very few of these studies have focused on pregnant women who are an index for both horizontal and vertical transmission of HBV and HDV. These studies reported low levels of anti-HDV antibodies in pregnant women of 2.3-4.0% [9, 29]. These values are low compared to the rate of 32.3% anti-HDV antibody prevalence which we obtained in our study. This difference could be due to the fact that the previous studies were conducted in the Yaoundé an urban area, where there are better living conditions, higher level of education, awareness and knowledge of hepatitis B compared to the semi-urban and rural areas that were included in our study. In comparison of anti-HDV antibody rates among pregnant women in other African countries such as Benin (11.4%), Mauritania (14.7%), Gabon (15.6%), the Central African Republic (21. 4%)[33-36], our result is higher at 32.3%. Our findings show that the number of children, marital status, presence of tattoos or scarifications and history of surgery are factors associated with the positivity of anti-HDV

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

antibodies. Besombes and colleagues reported in 2020 that individuals with more than 10 sexual casual partners and those who received injections were most at risk of getting HDV [16]. The rates of HBV serological markers in anti-HDV-positive individuals showed that anti-HBc antibodies and anti-HBe antibodies were statistically associated with anti-HDV positivity in this study. Similarly, a majority of women with the HBeAg-negative/HBeAb-positive serological profile, had plasma HDV RNA viral load ranging from 10000 to 35000 copies/mL. Limitations of this study include the performance of the test HDV antibody test kit and the lack of a national testing algorithm for diagnosis of HDV infection in Cameroon. Conclusion In conclusion, the results of this study show that in spite of the availability of the hepatitis B vaccine in the EPI in Cameroon, HBV infection is moderately endemic (6.7%) in the Centre Region of Cameroon, while HDV rate is 32.3% among pregnant women. Increasing number of casual sexual partners and high level of HDV viremia, may favour horizontal and vertical cotransmission of HDV in this population. Hence, the need to intensify awareness and control strategies for hepatitis B and D among pregnant women and contribute to the global elimination of hepatitis B. Acknowledgement We acknowledge the financial and technical contributions from the Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS to carry out this study. Funding was provided by the Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS (CIRCB). And the WHO Sasakawa 2019 Health Prize to Judith Torimiro. References 1. WHO, Key facts on hepatitis B. 2020. 2. Sawadogo, A., et al., Seroprevalence of hepatitis D virus infection in a population of blood donors carrying HBs Antigen at the Bobo-Dioulasso Regional Blood Transfusion

Center. Journal Africain d'Hépato-Gastroentérologie, 2016. 10(1): p. 31-33.

- 313 3. Sahin, A., et al., *Anti-HDV seroprevalance among patients with previous HBV infection.*
- North Clin Istanb, 2018. **5**(2): p. 132-138.
- 315 4. Medhat, A., et al., Acute viral hepatitis in pregnancy. Int J Gynaecol Obstet, 1993.
- **40**(1): p. 25-31.
- 5. Dulger, A.C., et al., High prevalence of chronic hepatitis D virus infection in Eastern
- 318 Turkey: urbanization of the disease. Arch Med Sci, 2016. 12(2): p. 415-20.
- 319 6. A.T. Kabamba, C.M.M., C.M. Nyembo, B.M. Kabamba Et And A.O. Longanga,
- Hepatitis D seroprevalence among people with chronic hepatitis B in Lubumbashi
- 321 *(DRC)*. 2020.
- 322 7. Stockdale, A.J., et al., Prevalence of hepatitis D virus infection in sub-Saharan Africa:
- *a systematic review and meta-analysis.* Lancet Glob Health, 2017. **5**(10): p. e992-e1003.
- 324 8. Daw, M.A., et al., The Epidemiology of Hepatitis D Virus in North Africa: A Systematic
- 325 Review and Meta-Analysis. ScientificWorldJournal, 2018. 2018: p. 9312650.
- 326 9. Torimiro, J.N., et al., Rates of HBV, HCV, HDV and HIV type 1 among pregnant women
- and HIV type 1 drug resistance-associated mutations in breastfeeding women on
- *antiretroviral therapy.* BMC Pregnancy Childbirth, 2018. **18**(1): p. 504.
- 329 10. WHO, Key facts on hepatitis D.2022.
- 330 11. Zanetti, A.R., et al., Perinatal transmission of the hepatitis B virus and of the HBV-
- associated delta agent from mothers to offspring in northern Italy. J Med Virol, 1982.
- **9**(2): p. 139-48.
- Huang, Y.H., et al., *Phylogenetic analysis to document a common source of hepatitis D*
- virus infection in a mother and her child. Zhonghua Yi Xue Za Zhi (Taipei), 1999.
- **62**(1): p. 28-32.
- 336 13. Sellier, P., et al., Untreated highly viraemic pregnant women from Asia or sub-Saharan
- Africa often transmit hepatitis B virus despite serovaccination to newborns. Liver Int,
- 338 2015. **35**(2): p. 409-16.
- 339 14. Sellier, P.O., et al., Hepatitis B Virus-Hepatitis D Virus mother-to-child co-
- transmission: A retrospective study in a developed country. Liver Int, 2018. **38**(4): p.
- 341 611-618.
- 342 15. Yuan, J., et al., Antepartum immunoprophylaxis of three doses of hepatitis B
- immunoglobulin is not effective: a single-centre randomized study. J Viral Hepat, 2006.
- **13**(9): p. 597-604.
- 345 16. Besombes, C., et al., *The epidemiology of hepatitis delta virus infection in Cameroon*.
- 346 Gut, 2020. **69**(7): p. 1294-1300.

- 347 17. Stockdale, A.J., et al., The global prevalence of hepatitis D virus infection: Systematic
- 348 review and meta-analysis. J Hepatol, 2020. **73**(3): p. 523-532.
- 349 18. Bigna, J.J., et al., Seroprevalence of hepatitis B virus infection in Cameroon: a
- systematic review and meta-analysis. BMJ Open, 2017. 7(6): p. e015298.
- 351 19. CAMPHIA 2017 population impact assessment of HIV in Cameroon,. 2020.
- 352 20. Directorate for Disease Control, the E.e.l.P.-D., Monitoring Report on Key Health
- Indicators in Cameroon in 2019. 2022.
- 354 21. Butler, E.K., et al., *High prevalence of hepatitis delta virus in Cameroon*. Sci Rep, 2018.
- **8**(1): p. 11617.
- Pourhoseingholi, M.A., M. Vahedi, and M. Rahimzadeh, Sample size calculation in
- *medical studies.* Gastroenterol Hepatol Bed Bench, 2013. **6**(1): p. 14-7.
- 358 23. Groc, S., et al., High prevalence and diversity of hepatitis B and hepatitis delta virus in
- 359 *Gabon.* J Viral Hepat, 2019. **26**(1): p. 170-182.
- 360 24. Lingani, M., et al., The changing epidemiology of hepatitis B and C infections in
- Nanoro, rural Burkina Faso: a random sampling survey. BMC Infect Dis, 2020. **20**(1):
- 362 p. 46.
- 363 25. Sone, L.H.E., et al., Prevalence and Identification of Serum Markers Associated with
- Vertical Transmission of Hepatitis B in Pregnant Women in Yaounde, Cameroon. Int J
- 365 MCH AIDS, 2017. **6**(1): p. 69-74.
- 366 26. Eyong, E.M., et al., The prevalence of HBsAg, knowledge and practice of hepatitis B
- prevention among pregnant women in the Limbe and Muyuka Health Districts of the
- South West region of Cameroon: a three-year retrospective study. Pan Afr Med J. 2019.
- **36**9 **32**: p. 122.
- 370 27. Mawouma, A.R.N., et al., [Factors associated with hepatitis B infection in pregnant
- women at health facilities in the health district of Mokolo/Far North of Cameroon]. Pan
- 372 Afr Med J, 2022. 41: p. 61.
- 373 28. Gatchalian, S., et al., A new DTPw-HBV/Hib vaccine is immunogenic and safe when
- administered according to the EPI (Expanded Programme for Immunization) schedule
- and following hepatitis B vaccination at birth. Hum Vaccin, 2005. 1(5): p. 198-203.
- 376 29. Ndumbe, P.M., *Hepatitis D in Yaounde, Cameroon*. Apmis, 1991. **99**(2): p. 196-8.
- 377 30. Noubissi-Jouegouo, L., et al., Evolutionary trends in the prevalence of anti-HDV
- antibodies among patients positive for HBsAg referred to a national laboratory in
- 379 *Cameroon from 2012 to 2017.* BMC Res Notes, 2019. **12**(1): p. 417.

- 31. Luma, H.N., et al., *Prevalence and Characteristics of Hepatitis Delta Virus Infection in*381 *a Tertiary Hospital Setting in Cameroon.* J Clin Exp Hepatol, 2017. **7**(4): p. 334-339.
- Foupouapouognigni, Y., et al., *Endemicity and genetic diversity of Hepatitis delta virus among Pygmies in Cameroon, Central Africa.* BMC Res Notes, 2022. **15**(1): p. 87.
- 33. Mansour, W., et al., *Prevalence, risk factors, and molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in Mauritania.* J Med

 Virol, 2012. **84**(8): p. 1186-98.
- 34. Makuwa, M., et al., Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol, 2008. **46**(2): p. 754-390 6.
- 35. Komas, N.P., et al., Hepatitis B and hepatitis D virus infections in the Central African
 Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing
 spread in asymptomatic young adults. PLoS Negl Trop Dis, 2018. 12(4): p. e0006377.
- 36. De Paschale, M., et al., *Prevalence of HBV, HDV, HCV, and HIV infection during* pregnancy in northern Benin. J Med Virol, 2014. **86**(8): p. 1281-7.

Table 1: Characteristics of the study population

397

398

		HBsAg		
Variables		Negative (%)	Positive (%)	p-value
Age (years)	15-20	209 (91.2)	19 (8.8)	
Mean = 27 years	21-25	580 (92.2)	49 (7.8)	
	26-30	507 (94.9)	27 (5.1)	0,21
	31-35	360 (93.0)	27 (7.0)	
	36-40	172 (94.0)	11 (6.0)	
	41-45	31 (100.0)	0 (0)	
Gestational age	1-14	527(92.1)	45(7.9)	0.017*
(weeks)	15-28	940(94.4)	65(5.6)	
Mean = 18 weeks	29-42	374(90.1)	41(9.9)	
Hepatitis B	Not vaccinated	1779(93.04%)	133(7.0)	0.637
vaccination	1 Dose	10(100.0%)	0(0)	
	2 Doses	14(100.0%)	0(0)	
	3 Doses	56(0.58%)	0(0)	
Location of health	urban	1169(94.88%)	63(5.1)	0.016*
institution/study	semi-urban	263(91.96%)	23(8.0)	
site	rural	427(90.08%)	47(9.9)	

^{*.} The Chi-square statistic is significant at the .05 level.

Table 2: Distribution of viral infections (HCV, HDV, and HIV) and serological markers of hepatitis B infection among HBsAg-positive pregnant women

		Presence of anti-HDV antibodies		
Serological markers		Negative (%)	Positive (%)	P-value
Anti-HIV	Negative	80(68.4)	37(31.6)	0.612
	Positive	8(61.5)	5(38.46)	
Anti-HCV	Negative	88(68.8)	40(31.2)	0.119
	Positive	0(0)	2(100.0)	
HBeAg	Negative	82(69.5)	36(30.5)	0.169
	Positive	6(50.0)	6(50.0)	
HBc antibodies	Negative	2(25.0)	6(75.0)	0.008*
	Positive	86(70.5)	36(29.5)	
HBe antibodies	Negative	9(36.0)	16(64.0)	0.001*
	Positive	79(75.2)	26(24.8)	
HBeAg-/HBeAb -		8(44.4)	10(55.6)	0.005*
HBeAg+/HBeAb -		0(0)	6(100.0)	
HBeAg-/HBeAb +		75(75.3)	26(25.7)	
HBeAg+/HBeAb +		5(100.0)	0(0)	

Note

404

405 406

408

409

402

403

+: positive;

407 -: negative;

*. The Chi-square statistic is significant at the .05 level.

Table 3: Variation in the prevalence of hepatitis delta according to the clinical characteristics of pregnant women

Variable		Presence of anti-HDV antibodies		
		Negative (%)	Positive (%)	p-value
	15-20	16(84.2)	3 (15.8)	0.50
Age Group (years)	21-25	31 (66.0)	16 (34.0)	_
Mean = 26 years	26-30	17 (60.7)	11 (39.3)	_
_	31-35	18 (69.2)	8 (30.8)	_
_	36-40	6 (60.0)	4 (40.0)	_
Gestational age (weeks)	1-14	18 (69.2)	8 (30.2)	0.92
Mean: 22 (weeks)	15-28	34 (68.0)	16 (32.0)	_
_	29-42	36 (66.7)	18 (33.3)	_
Number of life births	0	40 (75.5)	13 (24.5)	0.030
_	1	26 (72.2)	10 (27.8)	_
_	2	10 (62.5)	6 (37.5)	_
_	3	11 (55.0)	9 (45.0)	_
_	4	1 (100.0)	0 (0.0)	_
_	5+	0 (0.0)	4 (100.0)	_
Marital status	life alone	46 (83.6)	9 (16.4)	0.001*
_	married life	42 (56.0)	33 (44.0)	_
Knowledge of tattoo	yes	6 (40.0)	9 (60.0)	0.015*
	no	82 (71.3)	33 (28.7)	_
History of surgical	yes	19 (90.5)	2 (9.5)	0.015*
operations	no	69 (63.3)	40 (36.7)	
Knowledge of female	yes	5 (100.0)	0 (00.0)	0.115
circumcision	no	83 (66.4)	42 (33.6)	
Use of alcohol	yes	39 (68.4)	18 (31.6)	0.87
	no	49 (67.1)	24 (32.9)	
Aware of hepatitis B	no one knows	2 (100.0)	0 (00.0)	0.189
status of close people	husband	15 (60.0)	10 (40.0)	
-	family member	0 (00.0)	2 (100.0)	_
_	friend	46 (64.8)	25 (35.2)	_
		` ′	` ′	

Note

412

413

414 415

410

^{*.} The Chi-square statistic is significant at the .05 level.

Table 4: Plasma HDV RNA viral load as a function of the serological profile of HBeAb and HBeAg markers

416

417

Serological profile		HDV RNA viral load (copies/mL)			
	Not detected	< 15	(15-1000)	(1000-10000)	(10000-35000)
HBeAg-/HBeAb -	5(33.33%)	0(0.0%)	2(40.0%)	2(40.0%)	0(0.0%)
HBeAg+/HBeAb -	1(6.67%)	0(0.0%)	1(20.0%)	0(0.0%)	1(20.0%)
HBeAg-/HBeAb +	9(60.0%)	4(100.0%)	2(40.0%)	3(60.0%)	4(80.0%)
Total	15	4	5	5	5



Figure 1: Map of ten regions of Cameroon.

Figure 1




Figure 2: Diagram showing procedure of screening for HBsAg and antibodies to and RNA of HDV of pregnant women.

Figure 2